Mesoblast Ltd Sp ADR (MBLTY) 15.6000 $MBLTY
Global Ischemic Stroke Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w6cj3m/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Acorda Therapeutics, Inc. - Acticor Biotech - advanceCor GmbH - AGY Therapeutics, Inc. - Angion Biomedica Corp. - AstraZeneca PLC - Athersys, Inc. - Biogen Idec Inc. - BioTime, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - International Stem Cell Corporation - Laboratoires Pierre Fabre SA - Lumosa Therapeutics Co., Ltd. - MediaPharma s.r.l. - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neurotec Pharma SL - NeuroVive Pharmaceutical AB - Panacea Pharmaceuticals, Inc. - Pharmicell Co., Ltd. - PhytoHealth Corporation - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Simcere Pharmaceutical Group - Stemedica Cell Technologies, Inc. - Vicore Pharma AB - Virogenomics, Inc. For more information visit http://www.researchandmarkets.com/research/w6...mic_stroke
BIIB: 391.24 (-3.11), ACOR: 30.04 (+0.14), GSK: 44.77 (-0.22), AZN: 69.29 (-0.81), ATHX: 1.27 (-0.01), CUR: 1.70 (-0.04)
Mesoblast Cell Therapy Reduces Inflammation And Reverses Coronary Artery Dysfunction In Rheumatoid Arthritis Preclinical Study
GlobeNewswire - Tue May 12, 4:08AM CDT
Mesoblast Limited (ASX: MSB, USOTC:MBLTY) today announced publication of results in the May issue of the peer-reviewed journal PLOS One showing that its proprietary allogeneic mesenchymal precursor cells (MPCs) can reduce inflammation and reverse abnormal function of blood vessels, including the coronary arteries, in a previously published sheep model of rheumatoid arthritis. Since patients with rheumatoid arthritis have an approximately 50% higher risk of death from cardiovascular disease than the general population, these results suggest that the anti-inflammatory effect of MPC therapy may have an additional benefit in reducing cardiovascular risk associated with rheumatoid arthritis.
Repairs To The Heart: The Needle Or The Knife?
Keith Williams - at Seeking Alpha - Mon May 04, 11:37AM CDT
SSH: 4.29 (+0.07), NBS: 2.38 (+0.07), CLDN: 2.18 (-0.17)
Global Graft Versus Host Disease (GVHD) Pipeline Report 2015 - Analysis of 43 Companies & 66 Drug Profiles
M2 - Mon Apr 27, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjmb6v/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbGenomics International, Inc. - Adienne Pharma & Biotech - Alder Biopharmaceuticals Inc. - Alexion Pharmaceuticals, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Bellicum Pharmaceuticals, Inc. - Biogen Idec Inc. - Dr. Falk Pharma GmbH - Enlivex Therapeutics Ltd - Escape Therapeutics, Inc. - F. Hoffmann-La Roche Ltd. - Generon (Shanghai) Corporation Ltd. - Lycera Corp. - Mesoblast Limited - Millennium Pharmaceuticals, Inc. - MSM Protein Technologies, Inc. - Neopharm Ltd. - NeoStem, Inc. - Novartis AG - Omni Bio Pharmaceutical Inc. - Pharmacyclics, Inc. - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - R-Tech Ueno, Ltd. - REGiMMUNE Corporation - Targazyme, Inc. - Therapix Biosciences Ltd - Tobira Therapeutics, Inc. - Xenikos B.V. For more information visit http://www.researchandmarkets.com/research/bj...ersus_host
BIIB: 391.24 (-3.11), PCYC: 255.42 (-0.50), PSTI: 2.68 (-0.01), NBS: 2.38 (+0.07), ALDR: 39.84 (+4.35), BLCM: 23.02 (-1.37), ALXN: 160.56 (-1.13), ATHX: 1.27 (-0.01), TBRA: 14.00 (+0.55), NVS: 103.75 (-0.15)
Global Bone Marrow Transplantation Pipeline Review 2015 - 12 Companies & 14 Drug Profiles
M2 - Mon Apr 27, 4:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dz5gfs/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Anchor Therapeutics, Inc. - Boryung Pharmaceutical Co., Ltd. - Cantex Pharmaceuticals, Inc. - Cellerant Therapeutics, Inc. - Cleveland BioLabs, Inc. - Compugen Ltd. - Mesoblast Limited - Pluristem Therapeutics Inc. - Proteonomix, Inc. - Spectrum Pharmaceuticals, Inc. - Taiga Biotechnologies, Inc. - Wellstat Therapeutics Corporation Drug Profiles - (filgrastim plerixafor) - ATI-2341 - BR-05001 - CBLB-612 - Cell Therapy for Bone Marrow Transplantation - CGEN-15001 - melphalan - MPC-CBE - PGX-100 - PLX-RAD - PN-951 - Protein for Bone Marrow Transplantation - romyelocel-L - Small Molecules to Inhibit Perforin for Bone Marrow Transplantation For more information visit http://www.researchandmarkets.com/research/dz...one_marrow
PSTI: 2.68 (-0.01), CGEN: 6.45 (-0.03), SPPI: 6.68 (-0.14), CBLI: 1.99 (unch)
Global Stem Cell Therapy Market Forecasts and Trends Report 2015-2020 - Cardiology, Oncology, Neurology, Diabetes, Orthopedics & Hematology
M2 - Thu Apr 23, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bvcjlr/stem_cell_therapy) has announced the addition of the "Stem Cell Therapy Global Market Forecast (2014-2020)" report to their offering. This report analyzes the global markets for Stem Cell Therapeutics. The report provides the standard and the tailored research methodology approach. The market overview offers in depth analysis for the regional and country level analysis, for instance North America (U.S., and Canada), Europe (Germany, France, Italy, U.K. and Spain), Asia-Pacific (China, Japan, India, South Korea and Rest of APAC) and Rest of the World (Middle East, Africa and Latin America). Annual estimations and forecasts are provided from the year 2012 to 2020 for each given segments and sub segments. Market data derived from the authenticated and reliable sources subjected to validation from the industry experts. The report also analyzes the market by discussing market dynamics such as drivers, constraints, opportunities, threats, challenges and other market trends. Competitive landscaping provides the recent activities performed by the active players in the market. Activities such as product launch, agreements, joint ventures, partnerships, acquisitions and mergers, other activities. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Analysis 4 Porters Five Force Analysis 5 Stem Cell Therapy Market by Applications 5.1 Cardiology 5.2 Oncology 5.3 Neurology 5.4 Diabetes 5.5 Orthopedics 5.6 Hematology 6 Stem Cell Therapy Market by Therapy Type 6.1 Autologous Stem Cell Therapy 6.2 Allogenous Stem Cell Therapy 6.3 Syngenous Stem Cell Therapy 7 Geographical Segmentation 8 Vendor Landscaping 9 Company Profiles - Aastrom Biosciences Inc. - Advanced Cell Technologies, Inc. - Celgene Corporation - Fibrocell Science, Inc. - Medipost - Mesoblast Ltd. - Pharmicell - Stem Cell Technologies For more information visit http://www.researchandmarkets.com/research/bv...ll_therapy
FCSC: 4.02 (+0.01), CELGZ: 2.60 (-0.10)
Orthopedics (Devices & Materials) - Global Trends, Estimates and Forecasts, 2013-2019
M2 - Tue Apr 21, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3mk33m/orthopedics) has announced the addition of the "Orthopedics (Devices & Materials) - Global Trends, Estimates and Forecasts, 2013-2019" report to their offering. Global Orthopedics (Devices and Material) market is estimated to reach US$57.2 billion by 2017. Devices types; Joints (Repair & Replacement) Industry market is worth US$40.2 billion by 2017, growing at a CAGR of 8.9% for the analysis period 2013-2019 respectively. The Americas region accounts for highest percentage approximately 56.6% (2016) of global share while Europe follows next with nearly 19.7% (2019) of the market. Asia-Pacific is the fastest growing region with a CAGR of 10.4% driving a market value of US$4.7 billion by 2016. By Material types; Orthopedics Biomaterials accounts for 48.3% of the market share and the rest is anticipated for Orthopedic Braces & Splints and Orthopedic Accessories. The report Orthopedics (Devices & Materials) - Global Trends, Estimates and Forecasts, 2013-2019' reviews the latest trends in orthopedics devices with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for healthcare sector investments. The study reveals profitable investment strategies for market start-ups, pharmaceutical/biotechnology companies, laboratories, Contract/Clinical/Commercial Research Organizations (CROs), government/academic organizations, consulting firms, database buyers and many more in preferred locations. The report primarily focuses on: - Emerging Market Trends - Advancements in the Technological Space - Market Demand of The Segments (By-Region) - Key Growth Areas and Market Size - Region-Wise Demand Factor - Key Competitors Edge - Investment Strategies Companies Mentioned: Partial List for Each region The Americas - Aesculap, Inc. - Amedica Corp. (Usa) - Arthrocare Corporation (Usa) - Biomet, Inc. (Usa) - Conmed Corp (Usa) - Corin Group Plc (Usa) - Depuy Synthess, Inc. (Usa) - Donjoy, Inc. (Usa) - Exactech, Inc. (Usa) - Globus Medical, Inc. (Usa) Europe - Aap Implantate Ag (Germany) - Metoxit Ag (France) - Arthro Kinetics Plc (Germany) - Biedermann Motech Gmbh & Co Kg (Germany) - Biotechni (France) - Dot Gmbh (Germany) - Eska Orthodynamics Gmbh (Germany) - Gruppo Bioimpianti S.R.L. (Italy) - Inion Oy (Finland) - Lima-Lto Medical Systems (Italy) - Mathys Ltd. Bettlach (Switzerland) - Medacta International Sa (Switzerland) - Memometal Technologies (United Kingdom) - Metoxit Ag (France) Asia-Pacific - Denyers International (Australia) - Mesoblast Limited (Australia) - Orthocare Pty Ltd (Australia) - Austofix Group Ltd (Australia) - Trauson Medical Instrument Co., Ltd (China) - Wuhan Dragonbio Orthopedic Products Co., Ltd. (China) - Canwell Medical Ltd (China) - Suzhou Ortho Instrument Co., Ltd. (China) - M J Surgical (India) Rest Of World - Hipokrat Inc. (Turkey) - Onur Medikal Ltd. (Turkey) For more information visit http://www.researchandmarkets.com/research/3m...rthopedics
GMED: 25.12 (-0.05), MDSY: 2.27 (-0.01), EXAC: 20.98 (-0.97), AMDA: 0.22 (unch)
Seeking Alpha's Biotech Weekly: Celgene Check-Up, Is Gilead The New Apple?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 17, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors geared up for earnings season, highlighted several...
SGYP: 3.52 (+0.04), BIIB: 391.24 (-3.11), ARWR: 6.29 (-0.02), AMGN: 162.36 (+0.38), MYL: 70.67 (-0.86), BMY: 67.64 (+0.19), CNCE: 14.13 (-0.05), CELG: 115.53 (+0.45), ATNM: 2.59 (+0.08), PFS: 18.04 (-0.16), NVIV: 13.06 (+0.31), GILD: 109.30 (+0.56), FWP: 34.65 (+0.24), GWPH: 112.25 (-0.07), IBM: 173.26 (-0.79), BAX: 69.36 (+0.32), AZN: 69.29 (-0.81), TEVA: 60.23 (-0.99)
Celgene's Play In Cell-Based Therapy/Regenerative Medicine Is Very Good News For Mesoblast
Keith Williams - at Seeking Alpha - Mon Apr 13, 1:26PM CDT
CELG: 115.53 (+0.45)
Great Timing For Athersys, Other Stem Cell Companies Amidst Improving Regulatory Landscape
ACCESSWIRE - Mon Apr 13, 8:35AM CDT
WHITEFISH, MT / ACCESSWIRE / April 13, 2015 / The field of regenerative medicine holds great promise for developing new treatments for notoriously difficult-to-treat diseases and conditions where small molecules, immunotherapies and other disciplines still haven't been able to deliver a safe and efficacious impact. For instance, Athersys, Inc. (NASDAQ:ATHX) is now less than two weeks away from top-line data from a Phase 2 international trial on patients suffering an ischemic stoke, an often devastating condition where there are no FDA-approved treatments beyond a four hour treatment window from time of occurrence. Mesoblast Ltd. (OTC: MBLTY)(ASX: MSB) has five product candidates based on specialized cells called mesenchymal lineage adult stem cells in, or ready for, late-stage trials targeting difficult conditions, including congestive heart failure. In a blitz of biotech deals in the waning days of March, stem cells hit the headlines with Fujifilm agreeing to acquire Cellular Dynamics International (NASDAQ: ICEL) for $307 million, a heavy 108% premium to the prior day's closing price of ICEL, to gain control of one of the aspiring leaders in the stem cell research business. This follows on the announcement in early March of the new Athersys-Chugai partnership.
ICEL: 16.55 (+0.03), TEVA: 60.23 (-0.99), ATHX: 1.27 (-0.01), MSB: 14.86 (-0.24)
Celgene And Mesoblast Enter Into Equity Placement and Right of First Refusal Agreement To Certain Disease Fields
GlobeNewswire - Sun Apr 12, 7:02PM CDT
Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today announced that the Company has entered into an Agreement with US-based Celgene Corporation, a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Pursuant to this Agreement, Celgene will purchase Mesoblast stock and has a six-month right of first refusal to certain disease fields.
CELGZ: 2.60 (-0.10)
Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 2.68 (-0.01), NBS: 2.38 (+0.07), OSIR: 17.29 (-0.18), BCLI: 3.66 (-0.04), MDVN: 122.90 (-0.47), INO: 7.97 (-0.02), CYTX: 0.66 (-0.02), STEM: 0.62 (+0.01), JUNO: 43.37 (-1.52), ATHX: 1.27 (-0.01), CUR: 1.70 (-0.04), BLUE: 154.42 (-2.98), VRTX: 126.21 (+3.21), AMGN: 162.36 (+0.38), KERX: 10.33 (+0.11), OMER: 20.88 (-0.01), KITE: 50.02 (-2.24), GILD: 109.30 (+0.56), MRK: 60.23 (+0.45), TEVA: 60.23 (-0.99)
Mesoblast Phase 3 Program For Degenerative Disc Disease To Include European Sites After Positive Meeting With European Medicines Agency
GlobeNewswire - Tue Apr 07, 7:25PM CDT
Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today announced that following positive feedback from its recent meeting with the European Medicines Agency (EMA), it intends to expand the Phase 3 clinical program of its product candidate MPC-06-ID in the treatment of chronic low back pain due to degenerative disc disease to include sites in the European Union (EU).
Mesoblast Key Patent Allowed in Japan for the Treatment of Heart Diseases, Stroke, and Other Vascular Conditions
GlobeNewswire - Thu Mar 26, 10:33PM CDT
Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today announced that the Japanese Patent Office has allowed a key patent covering the use of the Company's proprietary adult Mesenchymal Precursor Cells (MPCs) for the formation and repair of blood vessels in ischemic tissues. Japanese patent 2006-503990, entitled 'Perivascular Mesenchymal Precursor Cell Induced Blood Vessel Formation', covers the use of these cells derived from bone marrow, adipose tissue and dental pulp.
Mesoblast Selected for Fast Track Access to Potential Investment Incentives in Japan
GlobeNewswire - Wed Mar 18, 6:32PM CDT
Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that it has been selected by the Japan External Trade Organization (JETRO) as the only regenerative medicine company worldwide to receive fast track access to potential investment incentives across all levels of government in Japan. Mesoblast will receive a specially tailored market and government incentive roadmap aimed at providing a more attractive business environment.
MSB: 14.86 (-0.24)
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Pipeline Review 2015: 41 Companies
M2 - Tue Mar 03, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/pk77s7/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alcon, Inc. - Allergan, Inc. - AlphaMab Co., Ltd - Amakem NV - Avalanche Biotechnologies, Inc. - Bayer AG - BIOCAD - Boehringer Ingelheim GmbH - Charlesson LLC. - Circadian Technologies Limited - Clearside BioMedical, Inc. - EyeCyte, Inc. - F. Hoffmann-La Roche Ltd. - Genzyme Corporation - GlaxoSmithKline plc - iCo Therapeutics Inc. - Icon Bioscience, Inc. - Iconic Therapeutics, Inc. - Intas Pharmaceuticals Ltd. - Kala Pharmaceuticals, Inc. - Lpath, Inc. - Mesoblast Limited - Neurotech Pharmaceuticals, Inc. - Novartis AG - Ohr Pharmaceutical Inc. - Ophthotech Corp. - Oxford BioMedica plc - PanOptica, Inc. - Pfenex Inc. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/pk...eovascular
PFE: 33.99 (+0.05), OPHT: 52.02 (-0.56), GSK: 44.77 (-0.22), PFNX: 13.70 (+0.60), LPTN: 1.83 (+0.04), AGN: 240.22 (+2.88), AAVL: 35.10 (-0.85), OHRP: 2.73 (-0.02), NVS: 103.75 (-0.15)
IMPROVED SURVIVAL IN CHILDREN WITH GRAFT VERSUS HOST DISEASE WHO RESPOND TO MESOBLAST'S CELL THERAPY
GlobeNewswire - Sun Feb 15, 5:33PM CST
Results of 160 pediatric patients treated with Mesoblast's proprietary allogeneic Tier 1 product candidate MSC-100-IV for severe steroid-resistant acute Graft Versus Host Disease (aGVHD) were presented at the 2015 American Society for Blood and Marrow Transplantation meeting in San Diego on 14 February.
NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
CAPR: 6.68 (+0.09), OCAT: 6.21 (+0.01), VCEL: 3.12 (-0.14), PSTI: 2.68 (-0.01), NBS: 2.38 (+0.07), GSK: 44.77 (-0.22), IMUC: 0.48 (+0.01), KITE: 50.02 (-2.24), BAX: 69.36 (+0.32), ONCE: 56.86 (+0.06), JUNO: 43.37 (-1.52), ATHX: 1.27 (-0.01), CUR: 1.70 (-0.04)
Mesoblast Reports 2015 Half-Year Results
GlobeNewswire - Wed Feb 11, 4:49PM CST
Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today provided its 2015 half-year financial results and operational highlights. Mesoblast held cash reserves of $149.2 million at 31 December 2014.
Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure
M2 - Tue Feb 03, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/lb556t/regenerative) has announced the addition of the "Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure" report to their offering. Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets, approaches and biology are discovered. Improved health care, nutrition and preventive medicine in the last few decades have all helped in increasing life expectancy WW. However, this has not translated in any reduction in the incidences or prevalence of chronic or critical illnesses! On the contrary, the incidence of chronic diseases like diabetes, obesity, arthritis etc. as well as cancer and the maladies associated with aging (dementia, Alzheimer's etc.) are on the rise. Consequently the pharma industry continues to grow and is projected to achieve sales in excess of the trillion dollar mark by 2020. By the next decade, one field which is poised to bring a paradigm change in the way diseases are treated is the Stem cell therapy/Regenerative Medicine space. The number of companies and products in the clinic has reached a critical mass, warranting a close watch by those interested in keeping pace with the development of new medicines. This report describes the key growth drivers and reasons for why this sector is poised for the "golden dawn" and forecasts that in the coming years, the translation of stem cell research to the clinic and market and Stem Cell Technologies Will Begin to Break Through by 2017. Key Topics Covered: 1. Executive summary 2. Introduction 3. Tough Choice- Autologous vs. Allogenic " Therapies 4. Regulatory Scenario 5. Marketed Cell based/Stem Cell Products 6. Progress and Challenges 7. Merger and Acquisition- Gaining Momentum in Regenerative Space 8. Progress in Specific Therapy Areas Companies Mentioned - CESCA Therapeutics Inc. [KOOL] - JCR Pharmaceuticals [4552:JP] - Japan Tissue Engineering Co., Ltd [7774:JP] - Medipost Co. Ltd [078160:KS] - Mesoblast Ltd [MSB:AU] - OCATA Therapeutics Inc. [OCAT] - Orgenesis [ORGS] - Pluristem Therapeutics Inc [PSTI:IT] - TiGenix NV [ TIG:BB] For more information visit http://www.researchandmarkets.com/research/lb...generative
KOOL: 0.76 (-0.06), OCAT: 6.21 (+0.01), PSTI: 2.68 (-0.01)
Global Ischemic Stroke Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w6cj3m/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Acorda Therapeutics, Inc. - Acticor Biotech - advanceCor GmbH - AGY Therapeutics, Inc. - Angion Biomedica Corp. - AstraZeneca PLC - Athersys, Inc. - Biogen Idec Inc. - BioTime, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - International Stem Cell Corporation - Laboratoires Pierre Fabre SA - Lumosa Therapeutics Co., Ltd. - MediaPharma s.r.l. - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neurotec Pharma SL - NeuroVive Pharmaceutical AB - Panacea Pharmaceuticals, Inc. - Pharmicell Co., Ltd. - PhytoHealth Corporation - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Simcere Pharmaceutical Group - Stemedica Cell Technologies, Inc. - Vicore Pharma AB - Virogenomics, Inc. For more information visit http://www.researchandmarkets.com/research/w6...mic_stroke
BIIB: 391.24 (-3.11), ACOR: 30.04 (+0.14), GSK: 44.77 (-0.22), AZN: 69.29 (-0.81), ATHX: 1.27 (-0.01), CUR: 1.70 (-0.04)
Mesoblast Cell Therapy Reduces Inflammation And Reverses Coronary Artery Dysfunction In Rheumatoid Arthritis Preclinical Study
GlobeNewswire - Tue May 12, 4:08AM CDT
Mesoblast Limited (ASX: MSB, USOTC:MBLTY) today announced publication of results in the May issue of the peer-reviewed journal PLOS One showing that its proprietary allogeneic mesenchymal precursor cells (MPCs) can reduce inflammation and reverse abnormal function of blood vessels, including the coronary arteries, in a previously published sheep model of rheumatoid arthritis. Since patients with rheumatoid arthritis have an approximately 50% higher risk of death from cardiovascular disease than the general population, these results suggest that the anti-inflammatory effect of MPC therapy may have an additional benefit in reducing cardiovascular risk associated with rheumatoid arthritis.
Repairs To The Heart: The Needle Or The Knife?
Keith Williams - at Seeking Alpha - Mon May 04, 11:37AM CDT
SSH: 4.29 (+0.07), NBS: 2.38 (+0.07), CLDN: 2.18 (-0.17)
Global Graft Versus Host Disease (GVHD) Pipeline Report 2015 - Analysis of 43 Companies & 66 Drug Profiles
M2 - Mon Apr 27, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjmb6v/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbGenomics International, Inc. - Adienne Pharma & Biotech - Alder Biopharmaceuticals Inc. - Alexion Pharmaceuticals, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Bellicum Pharmaceuticals, Inc. - Biogen Idec Inc. - Dr. Falk Pharma GmbH - Enlivex Therapeutics Ltd - Escape Therapeutics, Inc. - F. Hoffmann-La Roche Ltd. - Generon (Shanghai) Corporation Ltd. - Lycera Corp. - Mesoblast Limited - Millennium Pharmaceuticals, Inc. - MSM Protein Technologies, Inc. - Neopharm Ltd. - NeoStem, Inc. - Novartis AG - Omni Bio Pharmaceutical Inc. - Pharmacyclics, Inc. - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - R-Tech Ueno, Ltd. - REGiMMUNE Corporation - Targazyme, Inc. - Therapix Biosciences Ltd - Tobira Therapeutics, Inc. - Xenikos B.V. For more information visit http://www.researchandmarkets.com/research/bj...ersus_host
BIIB: 391.24 (-3.11), PCYC: 255.42 (-0.50), PSTI: 2.68 (-0.01), NBS: 2.38 (+0.07), ALDR: 39.84 (+4.35), BLCM: 23.02 (-1.37), ALXN: 160.56 (-1.13), ATHX: 1.27 (-0.01), TBRA: 14.00 (+0.55), NVS: 103.75 (-0.15)
Global Bone Marrow Transplantation Pipeline Review 2015 - 12 Companies & 14 Drug Profiles
M2 - Mon Apr 27, 4:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dz5gfs/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Anchor Therapeutics, Inc. - Boryung Pharmaceutical Co., Ltd. - Cantex Pharmaceuticals, Inc. - Cellerant Therapeutics, Inc. - Cleveland BioLabs, Inc. - Compugen Ltd. - Mesoblast Limited - Pluristem Therapeutics Inc. - Proteonomix, Inc. - Spectrum Pharmaceuticals, Inc. - Taiga Biotechnologies, Inc. - Wellstat Therapeutics Corporation Drug Profiles - (filgrastim plerixafor) - ATI-2341 - BR-05001 - CBLB-612 - Cell Therapy for Bone Marrow Transplantation - CGEN-15001 - melphalan - MPC-CBE - PGX-100 - PLX-RAD - PN-951 - Protein for Bone Marrow Transplantation - romyelocel-L - Small Molecules to Inhibit Perforin for Bone Marrow Transplantation For more information visit http://www.researchandmarkets.com/research/dz...one_marrow
PSTI: 2.68 (-0.01), CGEN: 6.45 (-0.03), SPPI: 6.68 (-0.14), CBLI: 1.99 (unch)
Global Stem Cell Therapy Market Forecasts and Trends Report 2015-2020 - Cardiology, Oncology, Neurology, Diabetes, Orthopedics & Hematology
M2 - Thu Apr 23, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bvcjlr/stem_cell_therapy) has announced the addition of the "Stem Cell Therapy Global Market Forecast (2014-2020)" report to their offering. This report analyzes the global markets for Stem Cell Therapeutics. The report provides the standard and the tailored research methodology approach. The market overview offers in depth analysis for the regional and country level analysis, for instance North America (U.S., and Canada), Europe (Germany, France, Italy, U.K. and Spain), Asia-Pacific (China, Japan, India, South Korea and Rest of APAC) and Rest of the World (Middle East, Africa and Latin America). Annual estimations and forecasts are provided from the year 2012 to 2020 for each given segments and sub segments. Market data derived from the authenticated and reliable sources subjected to validation from the industry experts. The report also analyzes the market by discussing market dynamics such as drivers, constraints, opportunities, threats, challenges and other market trends. Competitive landscaping provides the recent activities performed by the active players in the market. Activities such as product launch, agreements, joint ventures, partnerships, acquisitions and mergers, other activities. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Analysis 4 Porters Five Force Analysis 5 Stem Cell Therapy Market by Applications 5.1 Cardiology 5.2 Oncology 5.3 Neurology 5.4 Diabetes 5.5 Orthopedics 5.6 Hematology 6 Stem Cell Therapy Market by Therapy Type 6.1 Autologous Stem Cell Therapy 6.2 Allogenous Stem Cell Therapy 6.3 Syngenous Stem Cell Therapy 7 Geographical Segmentation 8 Vendor Landscaping 9 Company Profiles - Aastrom Biosciences Inc. - Advanced Cell Technologies, Inc. - Celgene Corporation - Fibrocell Science, Inc. - Medipost - Mesoblast Ltd. - Pharmicell - Stem Cell Technologies For more information visit http://www.researchandmarkets.com/research/bv...ll_therapy
FCSC: 4.02 (+0.01), CELGZ: 2.60 (-0.10)
Orthopedics (Devices & Materials) - Global Trends, Estimates and Forecasts, 2013-2019
M2 - Tue Apr 21, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3mk33m/orthopedics) has announced the addition of the "Orthopedics (Devices & Materials) - Global Trends, Estimates and Forecasts, 2013-2019" report to their offering. Global Orthopedics (Devices and Material) market is estimated to reach US$57.2 billion by 2017. Devices types; Joints (Repair & Replacement) Industry market is worth US$40.2 billion by 2017, growing at a CAGR of 8.9% for the analysis period 2013-2019 respectively. The Americas region accounts for highest percentage approximately 56.6% (2016) of global share while Europe follows next with nearly 19.7% (2019) of the market. Asia-Pacific is the fastest growing region with a CAGR of 10.4% driving a market value of US$4.7 billion by 2016. By Material types; Orthopedics Biomaterials accounts for 48.3% of the market share and the rest is anticipated for Orthopedic Braces & Splints and Orthopedic Accessories. The report Orthopedics (Devices & Materials) - Global Trends, Estimates and Forecasts, 2013-2019' reviews the latest trends in orthopedics devices with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for healthcare sector investments. The study reveals profitable investment strategies for market start-ups, pharmaceutical/biotechnology companies, laboratories, Contract/Clinical/Commercial Research Organizations (CROs), government/academic organizations, consulting firms, database buyers and many more in preferred locations. The report primarily focuses on: - Emerging Market Trends - Advancements in the Technological Space - Market Demand of The Segments (By-Region) - Key Growth Areas and Market Size - Region-Wise Demand Factor - Key Competitors Edge - Investment Strategies Companies Mentioned: Partial List for Each region The Americas - Aesculap, Inc. - Amedica Corp. (Usa) - Arthrocare Corporation (Usa) - Biomet, Inc. (Usa) - Conmed Corp (Usa) - Corin Group Plc (Usa) - Depuy Synthess, Inc. (Usa) - Donjoy, Inc. (Usa) - Exactech, Inc. (Usa) - Globus Medical, Inc. (Usa) Europe - Aap Implantate Ag (Germany) - Metoxit Ag (France) - Arthro Kinetics Plc (Germany) - Biedermann Motech Gmbh & Co Kg (Germany) - Biotechni (France) - Dot Gmbh (Germany) - Eska Orthodynamics Gmbh (Germany) - Gruppo Bioimpianti S.R.L. (Italy) - Inion Oy (Finland) - Lima-Lto Medical Systems (Italy) - Mathys Ltd. Bettlach (Switzerland) - Medacta International Sa (Switzerland) - Memometal Technologies (United Kingdom) - Metoxit Ag (France) Asia-Pacific - Denyers International (Australia) - Mesoblast Limited (Australia) - Orthocare Pty Ltd (Australia) - Austofix Group Ltd (Australia) - Trauson Medical Instrument Co., Ltd (China) - Wuhan Dragonbio Orthopedic Products Co., Ltd. (China) - Canwell Medical Ltd (China) - Suzhou Ortho Instrument Co., Ltd. (China) - M J Surgical (India) Rest Of World - Hipokrat Inc. (Turkey) - Onur Medikal Ltd. (Turkey) For more information visit http://www.researchandmarkets.com/research/3m...rthopedics
GMED: 25.12 (-0.05), MDSY: 2.27 (-0.01), EXAC: 20.98 (-0.97), AMDA: 0.22 (unch)
Seeking Alpha's Biotech Weekly: Celgene Check-Up, Is Gilead The New Apple?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 17, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors geared up for earnings season, highlighted several...
SGYP: 3.52 (+0.04), BIIB: 391.24 (-3.11), ARWR: 6.29 (-0.02), AMGN: 162.36 (+0.38), MYL: 70.67 (-0.86), BMY: 67.64 (+0.19), CNCE: 14.13 (-0.05), CELG: 115.53 (+0.45), ATNM: 2.59 (+0.08), PFS: 18.04 (-0.16), NVIV: 13.06 (+0.31), GILD: 109.30 (+0.56), FWP: 34.65 (+0.24), GWPH: 112.25 (-0.07), IBM: 173.26 (-0.79), BAX: 69.36 (+0.32), AZN: 69.29 (-0.81), TEVA: 60.23 (-0.99)
Celgene's Play In Cell-Based Therapy/Regenerative Medicine Is Very Good News For Mesoblast
Keith Williams - at Seeking Alpha - Mon Apr 13, 1:26PM CDT
CELG: 115.53 (+0.45)
Great Timing For Athersys, Other Stem Cell Companies Amidst Improving Regulatory Landscape
ACCESSWIRE - Mon Apr 13, 8:35AM CDT
WHITEFISH, MT / ACCESSWIRE / April 13, 2015 / The field of regenerative medicine holds great promise for developing new treatments for notoriously difficult-to-treat diseases and conditions where small molecules, immunotherapies and other disciplines still haven't been able to deliver a safe and efficacious impact. For instance, Athersys, Inc. (NASDAQ:ATHX) is now less than two weeks away from top-line data from a Phase 2 international trial on patients suffering an ischemic stoke, an often devastating condition where there are no FDA-approved treatments beyond a four hour treatment window from time of occurrence. Mesoblast Ltd. (OTC: MBLTY)(ASX: MSB) has five product candidates based on specialized cells called mesenchymal lineage adult stem cells in, or ready for, late-stage trials targeting difficult conditions, including congestive heart failure. In a blitz of biotech deals in the waning days of March, stem cells hit the headlines with Fujifilm agreeing to acquire Cellular Dynamics International (NASDAQ: ICEL) for $307 million, a heavy 108% premium to the prior day's closing price of ICEL, to gain control of one of the aspiring leaders in the stem cell research business. This follows on the announcement in early March of the new Athersys-Chugai partnership.
ICEL: 16.55 (+0.03), TEVA: 60.23 (-0.99), ATHX: 1.27 (-0.01), MSB: 14.86 (-0.24)
Celgene And Mesoblast Enter Into Equity Placement and Right of First Refusal Agreement To Certain Disease Fields
GlobeNewswire - Sun Apr 12, 7:02PM CDT
Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today announced that the Company has entered into an Agreement with US-based Celgene Corporation, a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Pursuant to this Agreement, Celgene will purchase Mesoblast stock and has a six-month right of first refusal to certain disease fields.
CELGZ: 2.60 (-0.10)
Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 2.68 (-0.01), NBS: 2.38 (+0.07), OSIR: 17.29 (-0.18), BCLI: 3.66 (-0.04), MDVN: 122.90 (-0.47), INO: 7.97 (-0.02), CYTX: 0.66 (-0.02), STEM: 0.62 (+0.01), JUNO: 43.37 (-1.52), ATHX: 1.27 (-0.01), CUR: 1.70 (-0.04), BLUE: 154.42 (-2.98), VRTX: 126.21 (+3.21), AMGN: 162.36 (+0.38), KERX: 10.33 (+0.11), OMER: 20.88 (-0.01), KITE: 50.02 (-2.24), GILD: 109.30 (+0.56), MRK: 60.23 (+0.45), TEVA: 60.23 (-0.99)
Mesoblast Phase 3 Program For Degenerative Disc Disease To Include European Sites After Positive Meeting With European Medicines Agency
GlobeNewswire - Tue Apr 07, 7:25PM CDT
Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today announced that following positive feedback from its recent meeting with the European Medicines Agency (EMA), it intends to expand the Phase 3 clinical program of its product candidate MPC-06-ID in the treatment of chronic low back pain due to degenerative disc disease to include sites in the European Union (EU).
Mesoblast Key Patent Allowed in Japan for the Treatment of Heart Diseases, Stroke, and Other Vascular Conditions
GlobeNewswire - Thu Mar 26, 10:33PM CDT
Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today announced that the Japanese Patent Office has allowed a key patent covering the use of the Company's proprietary adult Mesenchymal Precursor Cells (MPCs) for the formation and repair of blood vessels in ischemic tissues. Japanese patent 2006-503990, entitled 'Perivascular Mesenchymal Precursor Cell Induced Blood Vessel Formation', covers the use of these cells derived from bone marrow, adipose tissue and dental pulp.
Mesoblast Selected for Fast Track Access to Potential Investment Incentives in Japan
GlobeNewswire - Wed Mar 18, 6:32PM CDT
Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that it has been selected by the Japan External Trade Organization (JETRO) as the only regenerative medicine company worldwide to receive fast track access to potential investment incentives across all levels of government in Japan. Mesoblast will receive a specially tailored market and government incentive roadmap aimed at providing a more attractive business environment.
MSB: 14.86 (-0.24)
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Pipeline Review 2015: 41 Companies
M2 - Tue Mar 03, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/pk77s7/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alcon, Inc. - Allergan, Inc. - AlphaMab Co., Ltd - Amakem NV - Avalanche Biotechnologies, Inc. - Bayer AG - BIOCAD - Boehringer Ingelheim GmbH - Charlesson LLC. - Circadian Technologies Limited - Clearside BioMedical, Inc. - EyeCyte, Inc. - F. Hoffmann-La Roche Ltd. - Genzyme Corporation - GlaxoSmithKline plc - iCo Therapeutics Inc. - Icon Bioscience, Inc. - Iconic Therapeutics, Inc. - Intas Pharmaceuticals Ltd. - Kala Pharmaceuticals, Inc. - Lpath, Inc. - Mesoblast Limited - Neurotech Pharmaceuticals, Inc. - Novartis AG - Ohr Pharmaceutical Inc. - Ophthotech Corp. - Oxford BioMedica plc - PanOptica, Inc. - Pfenex Inc. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/pk...eovascular
PFE: 33.99 (+0.05), OPHT: 52.02 (-0.56), GSK: 44.77 (-0.22), PFNX: 13.70 (+0.60), LPTN: 1.83 (+0.04), AGN: 240.22 (+2.88), AAVL: 35.10 (-0.85), OHRP: 2.73 (-0.02), NVS: 103.75 (-0.15)
IMPROVED SURVIVAL IN CHILDREN WITH GRAFT VERSUS HOST DISEASE WHO RESPOND TO MESOBLAST'S CELL THERAPY
GlobeNewswire - Sun Feb 15, 5:33PM CST
Results of 160 pediatric patients treated with Mesoblast's proprietary allogeneic Tier 1 product candidate MSC-100-IV for severe steroid-resistant acute Graft Versus Host Disease (aGVHD) were presented at the 2015 American Society for Blood and Marrow Transplantation meeting in San Diego on 14 February.
NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
CAPR: 6.68 (+0.09), OCAT: 6.21 (+0.01), VCEL: 3.12 (-0.14), PSTI: 2.68 (-0.01), NBS: 2.38 (+0.07), GSK: 44.77 (-0.22), IMUC: 0.48 (+0.01), KITE: 50.02 (-2.24), BAX: 69.36 (+0.32), ONCE: 56.86 (+0.06), JUNO: 43.37 (-1.52), ATHX: 1.27 (-0.01), CUR: 1.70 (-0.04)
Mesoblast Reports 2015 Half-Year Results
GlobeNewswire - Wed Feb 11, 4:49PM CST
Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today provided its 2015 half-year financial results and operational highlights. Mesoblast held cash reserves of $149.2 million at 31 December 2014.
Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure
M2 - Tue Feb 03, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/lb556t/regenerative) has announced the addition of the "Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure" report to their offering. Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets, approaches and biology are discovered. Improved health care, nutrition and preventive medicine in the last few decades have all helped in increasing life expectancy WW. However, this has not translated in any reduction in the incidences or prevalence of chronic or critical illnesses! On the contrary, the incidence of chronic diseases like diabetes, obesity, arthritis etc. as well as cancer and the maladies associated with aging (dementia, Alzheimer's etc.) are on the rise. Consequently the pharma industry continues to grow and is projected to achieve sales in excess of the trillion dollar mark by 2020. By the next decade, one field which is poised to bring a paradigm change in the way diseases are treated is the Stem cell therapy/Regenerative Medicine space. The number of companies and products in the clinic has reached a critical mass, warranting a close watch by those interested in keeping pace with the development of new medicines. This report describes the key growth drivers and reasons for why this sector is poised for the "golden dawn" and forecasts that in the coming years, the translation of stem cell research to the clinic and market and Stem Cell Technologies Will Begin to Break Through by 2017. Key Topics Covered: 1. Executive summary 2. Introduction 3. Tough Choice- Autologous vs. Allogenic " Therapies 4. Regulatory Scenario 5. Marketed Cell based/Stem Cell Products 6. Progress and Challenges 7. Merger and Acquisition- Gaining Momentum in Regenerative Space 8. Progress in Specific Therapy Areas Companies Mentioned - CESCA Therapeutics Inc. [KOOL] - JCR Pharmaceuticals [4552:JP] - Japan Tissue Engineering Co., Ltd [7774:JP] - Medipost Co. Ltd [078160:KS] - Mesoblast Ltd [MSB:AU] - OCATA Therapeutics Inc. [OCAT] - Orgenesis [ORGS] - Pluristem Therapeutics Inc [PSTI:IT] - TiGenix NV [ TIG:BB] For more information visit http://www.researchandmarkets.com/research/lb...generative
KOOL: 0.76 (-0.06), OCAT: 6.21 (+0.01), PSTI: 2.68 (-0.01)
